Physician profile
Michael Tobin
NPI 1629211644
$4,948.54
in general payments reported to CMS, 2019-2025
22 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,066 · 2021: $1,183 · 2022: $163 · 2023: $306 · 2024: $323 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $722.68 | 2021-2025 | Optimizer |
| Amgen INC. | $653.74 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $618.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $530.38 | 2019-2025 | |
| Pfizer INC. | $476.39 | 2019-2024 | |
| Heartflow, INC. | $444.01 | 2019-2025 | Ffrct |
| Amarin Pharma, INC. | $418.29 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $283.21 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.55 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $119.36 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $86.52 | 2019-2020 | |
| Esperion Therapeutics, INC. | $78.32 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $76.16 | 2019-2021 | |
| Astellas Pharma US INC | $63.38 | 2019-2020 | |
| Boston Scientific Corporation | $34.71 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.51 | 2019 | |
| Merck Sharp & Dohme LLC | $30.79 | 2021 | |
| Novo Nordisk INC | $29.34 | 2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $26.53 | 2019 | |
| Akcea Therapeutics, INC. | $24.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.88 | 2019 | |
| Arineta, INC | $7.68 | 2024 | Spotlight |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.